Compare Gilead Sciences, Inc. (GILD) vs Rent the Runway Inc (RENT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Rent the Runway Inc — how do they compare? Gilead Sciences, Inc. trades at $133.72 (market cap $163.51B), while Rent the Runway Inc trades at $3.32 (market cap $111.69M). The key difference: Gilead Sciences, Inc. is far larger — about 1464× Rent the Runway Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Rent the Runway Inc pays none. Which is the better fit depends on your goals.
| GILD | RENT | |
|---|---|---|
Market Cap | $163.51B | $111.69M |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $9.39 |
52-Week Low | $108.22 | $3.10 |
Enterprise Value | $178.05B | $271.79M |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
RENT stock trades at $3.24, down 2.99% on the day, with a bearish technical signal. The company reported Q1 2026 revenue growth of 29% year-over-year to $89.9 million, beating EPS expectations, but maintains negative net income and free cash flow. Leadership is in transition with a new interim CEO. The balance sheet shows negative shareholder equity of -$182.5 million and high debt levels, though the debt-to-asset ratio is projected to improve significantly by 2026.
The outlook is mixed: low valuation multiples (P/S 0.18) suggest potential upside, but persistent losses, high debt, and leadership changes pose significant risks. Analyst consensus is cautious with 42% buy ratings. Revenue growth and balance sheet improvements are key to watch, but the stock carries high risk due to profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Rent the Runway Inc
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →
